Investor Presentaiton
TIGIT Bispecific DGK Inhibitor
AR LDD
Oncology
Opdivo
Opdualag
AR LDD phase 1 design in 1L & 2L mCRPC
Key eligibility criteria
•
•
Open label¹: Assess the safety, tolerability and preliminary efficacy
Histologically or cytologically confirmed
adenocarcinoma of the prostate
Progressed on ADT and ≥ 1 prior secondary
hormonal therapy approved for CRPC
ECOG performance status (PS) 0 or 1
Dose escalation/Dose expansion
Primary endpoint
Safety and tolerability
Key secondary endpoints:
Confirmed Prostate Specific Antigen (PSA)
decline of ≥ 50% from baseline (PSA50)
Objective soft tissue response (CR or PR),
DOR, rPFS, PSA PFS
Part A
Dose escalation
Part B
Dose expansion
to optimize RP2D
Data anticipated in 2024
Ill Bristol Myers Squibb™
1. NCT04428788
Not for Product Promotional Use
105View entire presentation